Oxford-Serum malaria vaccine wins WHO's recommendation
The R21/Matrix-M malaria vaccine is an easily deployable vaccine that can be manufactured at mass scale at a modest cost, enabling as many as hundreds of millions of doses to be supplied to countries which are suffering a significant malaria burden, according to a news release posted on the Oxford University website.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Malaria | Malaria Vaccine | Oxford University | Pharmaceuticals | Vaccines | Websites